About Chemify
Chemify is a chem-tech pioneer founded in 2022 by Professor Lee Cronin, building on two decades of research at the University of Glasgow. Headquartered in Scotland, the company is creating a new digital foundation for chemistry through its proprietary Chemputation technology—a universal chemical programming language combined with advanced robotics and AI that translates digital code into real molecules. This breakthrough system enables fully automated Design–Make–Test–Analyze cycles, eliminating the synthesis bottleneck and accelerating the path from molecular concept to physical compound. At the core of Chemify's platform is a three-part technology stack: ML-based molecular design (Quantum Chemputation), route optimization software (ASSEMBLER), and automated synthesis executed through χDL (chi-DL), the world's first universal chemical programming language. Every design output is synthesis-aware and synthetically tractable, bridging the critical gap between conceptual design and physical makeability. The company's proprietary database contains pre-validated and automated reaction classes that ensure reliability and reproducibility. In 2025, Chemify opened its first Chemifarm in Maryhill, Glasgow—described as the world's most advanced automated synthesis facility. The company serves pharmaceutical, biotech, and materials science partners, enabling them to design and manufacture molecules faster, more reliably, and at scale. Chemify's vision is to make chemical design and synthesis as programmable and accessible as computing, positioning itself as the leading small molecule discovery and synthesis company globally. With over 150 employees—more than half holding advanced chemistry or engineering degrees—and backed by leading investors including Wing Capital, Insight Partners, Triatomic Capital, 8VC, and BlueYard Capital, Chemify is expanding globally to democratize access to novel molecules, drugs, and materials on-demand.
Mission & Story
Mission
Chemify's long-term vision is to make chemical design and synthesis as programmable and accessible as computing and to be the leading small molecule discovery and synthesis company on the planet – a 'Chemputation Engine.'
Founding Story
Chemify was founded in 2022 by Professor Lee Cronin, building on two decades of research at the University of Glasgow. The technology is based on 20+ years of research from the Cronin Group, which has published more than 500 seminal papers in the field of digitizing, programming, and automating chemistry. Professor Cronin holds the Regius Chair of Chemistry at the University of Glasgow and is a fellow of the Royal Society of Chemistry.
Who It Serves
Milestones & Awards
Recent Milestones
In 2025, Chemify opened its first Chemifarm in Maryhill, Glasgow – described as the world's most advanced automated synthesis facility. Global expansion is underway.
Key Partnerships
Company Details
- Founded
- 2022
- Headquarters
- Glasgow, Scotland, United Kingdom
- Employees
- 51-200
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.